(S (S (NP-SBJ Interferons/NNS) (VP induce/VBP (NP (ADJP-COOD (ADJP normal/JJ) and/CC (ADJP aberrant/JJ)) retinoic-acid/NN receptors/NNS type/NN alpha/NN) (PP in/IN (NP acute/JJ promyelocytic/JJ leukemia/NN cells/NNS))) :/:) (NP (NP potentiation/NN) (PP of/IN (NP (NP the/DT induction/NN) (PP of/IN (NP retinoid-dependent/JJ differentiation/NN markers/NNS)))) ./.))
(S (NP-SBJ (NP Treatment/NN) (PP of/IN (NP the/DT (ADJP (ADJP acute/JJ promyelocytic/JJ) (PRN -LRB-/-LRB- (ADJP APL/NN) -RRB-/-RRB-)) cell/NN line/NN NB4/NN)) (PP with/IN (NP-COOD (NP (NP interferon/NN alpha/NN) (PRN -LRB-/-LRB- (NP IFN-LRB-alpha-RRB-/NN) -RRB-/-RRB-)) ,/, (CONJP as/RB well/RB as/IN) (NP-COOD (NP IFN-LRB-beta-RRB-/NN) and/CC (NP (NP *?*/-NONE-) gamma/NN)) ,/,))) (VP results/VBZ (PP in/IN (NP (NP an/DT increased/VBN expression/NN) (PP of/IN (NP (NP the/DT transcripts/NNS) (VP coding/VBG (PP for/IN (NP-COOD (NP (NP retinoic-acid/JJ receptor/NN type/NN alpha/NN) (PRN -LRB-/-LRB- (NP RAR-LRB-alpha-RRB-/NN) -RRB-/-RRB-)) and/CC (NP the/DT leukemia-specific/JJ retinoic/JJ acid/NN receptor/NN PML-RAR/NN))))))))) ./.)
(S-COOD (S (NP-SBJ (NP-SBJ Transcriptional/JJ induction/NN) (PP of/IN (NP the/DT (NP-COOD (NP RAR-LRB-alpha-RRB-/NN) and/CC (NP PML-RAR/NN)) mRNAs/NNS))) (VP is/VBZ (ADJP-PRD rapid/JJ))) and/CC (S (NP-SBJ-19 it/PRP) (VP is/VBZ (VP parallelled/VBN (NP *-19/-NONE-) (PP by/IN (NP-LGS (NP an/DT increase/NN) (PP in/IN (NP the/DT corresponding/JJ proteins/NNS))))))) ./.)
(S (NP-SBJ-20 (NP Up-regulation/NN) (PP of/IN (NP (NP-COOD (NP RAR-LRB-alpha-RRB-/NN) and/CC (NP PML-RAR/NN)) gene/NN expression/NN)) (PP by/IN (NP IFN-LRB-alpha-RRB-/NN))) (VP is/VBZ (VP accompanied/VBN (NP *-20/-NONE-) (PP by/IN (NP-LGS (NP a/DT strong/JJ potentiation/NN) (PP in/IN (NP (NP the/DT induction/NN) (PP of/IN (NP (NP 2/CD retinoid-dependent/JJ granulocytic/JJ markers/NNS) ,/, i.e./FW ,/, (NP-COOD (NP granulocyte-colony-stimulating/JJ factor/NN receptor/NN mRNA/NN) and/CC (NP leukocyte/NN alkaline/NN phosphatase/NN)))))))))) ./.)
(S (ADVP However/RB) ,/, (NP-SBJ IFN-LRB-alpha-RRB-/NN) (VP does/VBZ not/RB (VP have/VB (NP any/DT effects/NNS) (PP on/IN (NP (NP the/DT retinoid-dependent/JJ regulation/NN) (PP of/IN (NP the/DT myeloid/JJ surface/NN markers/NNS (NP-COOD (NP CD11b/NN) and/CC (NP CD33/NN)))))))) ./.)
(S (NP-SBJ-COOD (NP (NP The/DT IFN-dependent/JJ increase/NN) (PP in/IN (NP RAR-LRB-alpha-RRB-/NN levels/NNS))) and/CC (NP (NP the/DT enhancing/JJ effect/NN) (PP of/IN (NP the/DT cytokine/NN)) (PP on/IN (NP retinoid-dependent/JJ granulocytic/JJ markers/NNS expression/NN)))) (VP may/MD (VP be/VB (NP-PRD (NP a/DT characteristic/NN) (PP of/IN (NP (ADJP PML-RAR/NN positive/JJ) cells/NNS))) ,/, (SBAR since/IN (S (NP-SBJ-21 the/DT phenomena/NNS) (VP are/VBP not/RB (VP observed/VBN (NP *-21/-NONE-) (PP in/IN (NP HL-60/NN promyelocytes/NNS)))))))) ./.)
(S (NP-SBJ-COOD (NP Interferons/NNS) (CONJP as/RB well/RB as/IN) (NP retinoids/NNS)) (VP inhibit/VBP (NP (NP the/DT growth/NN) (PP of/IN (NP NB4/NN cells/NNS))) ,/, (SBAR although/IN (S (NP-SBJ (NP the/DT 2/CD classes/NNS) (PP of/IN (NP compounds/NNS))) (VP do/VBP not/RB (ADVP significantly/RB) (VP interact/VBP (PP in/IN terms/NNS of/IN (NP anti-proliferative/JJ activity/NN))))))) ./.)
(S (NP-SBJ These/DT results/NNS) (VP suggest/VBP (NP (NP the/DT possible/JJ use/NN) (PP of/IN (NP (NP combinations/NNS) (PP between/IN (NP-COOD (NP IFNs/NNS) and/CC (NP retinoic/JJ acid/NN))))) (PP in/IN (NP (NP the/DT cyto-differentiating/JJ treatment/NN) (PP of/IN (NP APL/NN patients/NNS)))))) ./.)
